Nasus Pharma CFO Rubin Eyal leaves officer roles

The Chief Financial Officer and Executive Vice President has left Nasus Pharma Ltd, ending his Section 16 reporting status with no share transactions reported.

Rhea-AI Filing Summary

Nasus Pharma Ltd (NSRX) filed an Exit Form 4 reporting that Rubin Eyal, who served as Chief Financial Officer and Executive Vice President, ceased to serve in these roles effective September 18, 2026. As a result, he is no longer subject to Section 16 reporting obligations with respect to the company. The filing reports no share transactions.

Key Figures

Effective date of role cessation: September 18, 2026 Reported share transactions: 0 transactions Section 16 reporting status: No longer subject

3 metrics

Effective date of role cessation September 18, 2026 Date Rubin Eyal ceased to serve as CFO and Executive Vice President

Reported share transactions 0 transactions Exit Form 4 reports no acquisitions, dispositions, or other trades

Section 16 reporting status No longer subject Reporting person is no longer subject to Section 16 obligations for Nasus Pharma Ltd

Key Terms

Exit Form 4, Section 16, Securities Exchange Act of 1934

3 terms

Exit Form 4 regulatory

"This Exit Form 4 has been filed solely to report that Reporting Person"

Section 16 regulatory

"no longer subject to the reporting obligations under Section 16 of the"

Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.

Securities Exchange Act of 1934 regulatory

"reporting obligations under Section 16 of the Securities Exchange Act of 1934"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does this Form 4 disclose about Nasus Pharma Ltd (NSRX)?

It discloses that Rubin Eyal, formerly Chief Financial Officer and Executive Vice President of Nasus Pharma Ltd, ceased serving in these roles effective September 18, 2026 and therefore is no longer subject to Section 16 reporting obligations for the company.

Were any NSRX shares bought or sold in this Form 4 filing?

No. The Exit Form 4 for Nasus Pharma Ltd reports no share transactions. Its sole purpose is to document that the reporting person is no longer an officer and thus no longer subject to Section 16 reporting for the issuer.

Who is the reporting person in this NSRX Form 4 and what was his role?

The reporting person is Rubin Eyal, who served as Chief Financial Officer and Executive Vice President of Nasus Pharma Ltd. The filing notes that he has ceased serving in these roles as of September 18, 2026.

Why is this called an Exit Form 4 for Nasus Pharma Ltd (NSRX)?

It is an Exit Form 4 because it reports that the officer has ceased serving in his roles and is therefore no longer subject to the issuer-related reporting obligations under Section 16 of the Securities Exchange Act of 1934.

Is the NSRX Form 4 related to a Rule 10b5-1 trading plan?

No. The filing indicates that it is not made under a Rule 10b5-1 trading plan, and it reports no share purchases, sales, or other transactions for Nasus Pharma Ltd securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/21/2026 - 04:06 PM Accepted by SEC EDGAR 09/21/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rubin Eyal

(Last) (First) (Middle)

P.O. BOX 284

(Street)

TEL-AVIV-YAFO 6100201

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nasus Pharma Ltd [ NSRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)	X	Other (specify below)
	Chief Financial Officer		EVP

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

This Exit Form 4 has been filed solely to report that Reporting Person ceased to serve as the Chief Financial Officer and Executive Vice President of Nasus Pharma Ltd (the "Issuer"), effective as of September 18, 2026, and is no longer subject to the reporting obligations under Section 16 of the Securities Exchange Act of 1934, as amended, with respect to the Issuer.

	/s/ Eyal Rubin	09/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)